Search - tctmd.com

Displaying 1 - 20 of 82

Sort: Relevancy | Date

News Opinion CV Team Dispatch

December 2025 Dispatch for the CV Team

L.A. McKeown

December 23, 2025

News Daily News

Prevention Must Be Prioritized in Heart Failure Care: HFSA/ASPC

Yael L. Maxwell

August 18, 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for July 2025

Caitlin E. Cox

July 31, 2025

News Daily News

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

L.A. McKeown

July 24, 2025

News Daily News

Weight-Loss Medications Should Be Part of Cardiology’s Arsenal: ACC

Michael O'Riordan

June 25, 2025

News Daily News

Majority of US Adults Have High Long-term Risk of CVD: NHANES

Michael O'Riordan

June 13, 2025

News Opinion CV Team Dispatch

April 2025 Dispatch for the CV Team

L.A. McKeown

April 18, 2025

News Daily News ACC 2025

STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients

L.A. McKeown

March 29, 2025

News Opinion CV Team Dispatch

March 2025 Dispatch for the CV Team

L.A. McKeown

March 21, 2025

News Daily News

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Michael O'Riordan

January 22, 2025

News Daily News

Top General Cardiology and Prevention News of 2024

Caitlin E. Cox

December 30, 2024

News Daily News

Tirzepatide Bests Semaglutide for Weight Loss: SURMOUNT-5 Top-line Results

Michael O'Riordan

December 04, 2024

News Daily News

CMS Proposal Would Expand Medicare, Medicaid Coverage for GLP-1 Drugs

Todd Neale

November 27, 2024

News Opinion CV Team Dispatch

November 2024 Dispatch for the CV Team

L.A. McKeown

November 26, 2024

SUMMIT: Tirzepatide ‘Huge Win’ for HFpEF Patients With Obesity

News Conference News AHA 2024

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Michael O'Riordan

November 16, 2024

News Conference News HFSA 2024

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

Todd Neale

October 01, 2024

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

News Daily News

FINEARTS-HF: Topline Results Support Role for Finerenone in Mildly Reduced or Preserved EF

L.A. McKeown

August 05, 2024

News Daily News

Semaglutide Has Similar Benefits in Women and Men With HFpEF

Todd Neale

June 26, 2024

News Daily News

As Trends Reverse in CVD, AHA Warns of Soaring Costs and Illness

L.A. McKeown

June 05, 2024

Advertisement

December 2025 Dispatch for the CV Team

Prevention Must Be Prioritized in Heart Failure Care: HFSA/ASPC

TCTMD’s Top 10 Most Popular Stories for July 2025

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

Weight-Loss Medications Should Be Part of Cardiology’s Arsenal: ACC

Majority of US Adults Have High Long-term Risk of CVD: NHANES

April 2025 Dispatch for the CV Team

STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients

March 2025 Dispatch for the CV Team

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Top General Cardiology and Prevention News of 2024

Tirzepatide Bests Semaglutide for Weight Loss: SURMOUNT-5 Top-line Results

CMS Proposal Would Expand Medicare, Medicaid Coverage for GLP-1 Drugs

November 2024 Dispatch for the CV Team

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

FINEARTS-HF: Topline Results Support Role for Finerenone in Mildly Reduced or Preserved EF

Semaglutide Has Similar Benefits in Women and Men With HFpEF

As Trends Reverse in CVD, AHA Warns of Soaring Costs and Illness

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content